Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment

Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2015-07, Vol.68, p.56-60
Hauptverfasser:	Ampuero, Javier, Del Campo, José Antonio, Rojas, Lourdes, Calleja, José Luis, Cabezas, Joaquín, Lens, Sabela, Crespo, Javier, Forns, Xavier, Andrade, Raúl J, Fernández, Inmaculada, Buti, María, Millán, Raquel, Romero-Gómez, Manuel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Adverse event Aged Allergy and Immunology Anaemia Anemia - chemically induced Anemia - epidemiology Anemia - genetics Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Boceprevir Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Female Genetic Predisposition to Disease Hepatitis C Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Incidence Infectious Disease ITPA Lead-in-phase Male Membrane Transport Proteins - genetics Middle Aged Oligopeptides - adverse effects Oligopeptides - therapeutic use Pharmacogenomics Polymorphism Proline - adverse effects Proline - analogs & derivatives Proline - therapeutic use Prospective Studies Protease Inhibitors - adverse effects Protease Inhibitors - therapeutic use Pyrophosphatases - genetics Ribavirin - adverse effects Ribavirin - therapeutic use Risk Assessment SLC28 Telaprevir Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent cause for the discontinuation of therapy in patients with chronic hepatitis C infection. • We established a protective haplotype combining ITPA rs1127354 and SLC28A2 rs11854484 genotypes. • These findings could optimize the management of treatment-induced anaemia in hepatitis C infection.
ISSN:	1386-6532 1873-5967
DOI:	10.1016/j.jcv.2015.05.010